Journal of Medical Ethics · 2010 · 11 citations · 16 references
MedicineOncologyPharmacologyMedical EthicsPatient RightsResearch EthicsClinical Trial Approval ProcessesClinical Trial AuthorizationClinical Trial EthicsClinical TrialsClinical Trials In OncologyEnd-of-life Care EthicsAccess To Trial TreatmentsClinical Trial Access PolicyClinical Trial OversightImplementation Of Experimental TherapiesParticipant Right To Post-trial TreatmentPatient Participation RightsPost-trial Access EthicsTrial Methodology
The development of cancer therapies is a long and arduous process. Because it can take several years for a cancer agent to pass clinical testing and be approved for use, terminal cancer patients rarely have the time to see these experimental therapies become widely available. For most terminal cancer patients the only opportunity they have to access an experimental drug that could potentially improve their prognosis is by joining a clinical trial. Unfortunately, several aspects of clinical trial methodology that are set in place in order to optimise drug development for the benefit of future generations of cancer patients, pose significant limitations to current patient participation. Therefore, several terminal cancer patients believe that they should have the right to access experimental agents that have passed initial safety testing without having to participate in clinical trials. However, granting off-trial access to patients could be detrimental to the scientific process of drug development, and thus could pose significant risks to the health of future patients relying on sound research. Examining this matter through two divergent ethical lenses, rights-based ethics and communitarian ethics, may provide new insight into the issues surrounding the balance between the autonomous rights of current terminal cancer patients, and the needs of future patients and the values of society.
16
The Theory and Practice of Autonomy.
Laura W. Ekstrom, Gerald Dworkin · The Philosophical Review · 1993 · 1.1K citations
Scientific research is a moral duty
John Harris · Journal of Medical Ethics · 2005 · 328 citations · Full text
Quality of life in stage II breast cancer: an instrument for clinical trials.
Mark N. Levine, Gordon Guyatt, Michael Gent et al. · Journal of Clinical Oncology · 1988 · 225 citations
Medicine, Oncology, Breast Oncology +14
Consent and end of life decisions
John William Harris · Journal of Medical Ethics · 2003 · 109 citations · Full text